Britain Leads Europe In DeepTech Funding – So Why Do Its Best Companies Keep Leaving?

Europe’s deeptech sector has reached a valuation of €690 billion, and the UK is responsible for more of that than any other European country. Since 2019, British deeptech companies have raised $43.7 billion in venture capital, making the UK the third-largest destination for deeptech VC globally behind the US and China. Deep tech now accounts for 31% of all UK venture funding, triple its share from a decade ago. London alone raised $4.2 billion in 2026, nearly 25% of all European deeptech investment and more than double Paris and Berlin combined.

While the data looks strong, it masks a persistent pattern. A disproportionate share of the companies built on the back of that early-stage investment end up acquired by American buyers, relocated to access US markets or starved of the late-stage capital needed to scale independently. The UK builds world-class deeptech companies and then watches them leave. The pattern has continued for long enough that it now has its own name: the late-stage funding gap, estimated at between $4 billion and $11 billion annually.

The data specifies exactly where the break occurs – UK institutional investors participate in 57% of domestic deeptech seed rounds, by late stage, that figure drops to under 10%. The capital to get a company started in Britain is available, but the capital to keep it British is not.

Failing By Design, Not By Chance

The Royal Academy of Engineering’s State of UK Deep Tech report and the 2026 European Deeptech Report from Dealroom and Walden Catalyst trace back to identical core issues: the UK is proportionally strong at creating deeptech companies and proportionally weak at scaling them.

University spinouts account for 34% of the UK deeptech sector and generate 37% of enterprise value, confirming the research pipeline is working, even as the scaleup infrastructure around it hasn’t kept pace.

The initial numbers show that the UK really does have some solid advantages. British deeptech startups reach development milestones at 40% to 60% of the cost of their US equivalents, according to analysis presented to the British Consulate General. The sector is focused on areas with real long-term commercial value – AI (39% of deeptech funding), quantum computing (18% of global investment since 2020), biotech, medical devices – rather than chasing funding cycles. UK quantum has attracted 18% of all global quantum investment since 2020 from a country of 67 million people – the foundations aren’t the problem.

The problem is what happens at Series C and beyond, when the cheques needed to grow a deeptech company to commercial independence require institutional capital that British pension funds and sovereign wealth vehicles still allocate at a fraction of American equivalents. The US investors who fill that gap come with US expectations: listings on American exchanges, access to American talent pools, proximity to American customers. Accepting the capital often means accepting the trajectory.

What Would Change The Pattern

The policy response has historically focused on early-stage incentives: R&D tax credits, Innovate UK grants, the Enterprise Investment Scheme. These have worked, which is why the early-stage numbers look strong. What’s absent is equivalent support for the growth stage, where companies need patient capital over a five-to-ten-year horizon rather than venture returns over a three-to-five-year one.

The UK government committed £2 billion to AI over four years and approximately £1 billion toward sovereign compute capacity – neither of these is primarily a growth-stage deeptech instrument. The distance between building a world-class quantum or biotech company to Series B and having the domestic capital base to take it to independent scale hasn’t been closed by any announced policy so far.

The unvarnished truth of this discussion also involves a point the industry rarely admits: some of the UK’s best deeptech founders choose American acquisition not because they’re forced to but because British capital markets offer a less attractive exit pathway, British institutional investors are less willing to hold illiquid positions at scale, and the cultural default in British business remains selling early rather than building long.

Those aren’t problems that more government grants fix. They’re problems that require a different relationship between Britain’s institutional capital and its most ambitious technology companies.